Drug profile · INN
respiratory syncytial virus vaccine (bivalent, recombinant)
ABRYSVO
respiratory syncytial virus vaccine (bivalent, recombinant) (ABRYSVO) is a fusion glycoprotein f0 vaccine antigen.
EMA: approved Antiinfectives for systemic use (J07) J07BX05
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — respiratory syncytial virus vaccine (bivalent, recombinant)
- Class
- Antiinfectives for systemic use (J07)
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.83
Quick answer
respiratory syncytial virus vaccine (bivalent, recombinant) (ABRYSVO) is a fusion glycoprotein f0 vaccine antigen.
Key facts
INN respiratory syncytial virus vaccine (bivalent, recombinant)
Brand ABRYSVO
Mechanism Fusion glycoprotein F0 vaccine antigen
Target Fusion glycoprotein F0
Therapeutic class Antiinfectives for systemic use (J07)
ATC code J07BX05
Mechanism of action
Fusion glycoprotein F0 vaccine antigen
Primary target: Fusion glycoprotein F0
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is respiratory syncytial virus vaccine (bivalent, recombinant)?
respiratory syncytial virus vaccine (bivalent, recombinant) (ABRYSVO) is a fusion glycoprotein f0 vaccine antigen.
What is the brand name for respiratory syncytial virus vaccine (bivalent, recombinant)?
ABRYSVO is a marketed brand name for respiratory syncytial virus vaccine (bivalent, recombinant). Check FDA Drugs@FDA for the current US label holder and prescribing information.